• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding
Path Link

Therapies

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.

Tools & Resources

Find interactive tracking tools, discussion guides, and more.

Learn More

Personal Stories

Read Jenn's story Read about people who have traveled the road to better health.

Learn More


Goals of treating bleeding disorders

The main goals of treating bleeding disorders are to decrease the frequency and severity of bleeds, prevent long-term complications such as joint deformities and improve patient quality of life. These goals can be achieved by ensuring sufficient factor levels in the blood.

CSL Behring: Committed to coagulation therapies

The information in this site is brought to you by CSL Behring, a CSL Company. As a company with a long history creating a stable supply of life-saving therapies, CSL Behring provides plasma-derived and recombinant products used in the treatment of individuals with bleeding disorders, as well as the treatment of cardiac surgery patients and burn victims.

In fact, coagulation therapy is one of the keystones of our broad range of global therapies. Our extensive portfolio features over a dozen coagulation products used for the treatment of hemophilia A, hemophilia B, von Willebrand disease (VWD) and other factor deficiencies.



Last Updated: 8/5/2013 2:14 PM
  • E-mail
  • Print
  • Share